KRAS and malignant colon neoplasm: Considering that under the current clinical dosing regimen, cetuximab average steady state plasma concentration is estimated to be around 100 μg/ml [56, 57], our results indicate that the contribution of these miRNAs to cetuximab sensitivity in mutant KRAS HCT116 and SW480, and wild-type SW48 colon cancer cell lines could be relevant for future clinical studies in advancing the understanding of miRNA modulation as putative therapeutic approaches in colon cancer.